Product Name: GSK3Selectide
Product Number: PE-04AXL90
Size: 200 µg      Price:59.00
1 mg      $US119.00
Peptide Name: GSK3Selectide

Product Use: For assaying the phosphotransferase activity of Glycogen synthase-serine kinase 3 alpha (UniProt ID P49840).

Peptide Production Method: Solid-phase peptide synthesis

Peptide Sequence: KKGAPSPAPSPAP-pS-A

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1614.77 Da

Peptide Purity Percent after Synthesis and Purification: >90

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Peptide Recommended Enzyme: GSK3

Scientific Background: GSK3a is a protein-serine/threonine kinase of the CMGC group and GSK family. It is highly active following tyrosine phosphorylation within its activation T loop. Phosphorylation at Y279 increases phosphotransferase activity and promotes nuclear localization. Phosphorylation at S21 inhibits phosphotransferase activity. Through direct phosphorylation, it can inactivate glycogen synthase (for insulin regulation), CTNNB1/beta-catenin, APC, and AXIN1. GSK3 has been proposed as a tumour suppressor protein (TSP), since with loss of GSK3 there is an increase in WNT signalling, with a beta-catenin stabilization, leading to tumourigenesis. GSK3 has also been proposed to act as an oncoprotein (OP), as acute leukemia required GSK3 for cell proliferation. In most human cancers, it is up-regulated in expression about 1.6-times the rate observed for most protein kinases.